OncoMatch/Clinical Trials/NCT05128825
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Is NCT05128825 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies azenosertib for high-grade serous ovarian, fallopian tube or primary peritoneal cancer.
Treatment: azenosertib — This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: CCNE1 protein overexpression (positive Cyclin E1 protein status by IHC using Sponsor's assay)
Tumor testing (archival acceptable) confirms a positive Cyclin E1 protein status result determined by IHC using the Sponsor's investigational clinical trial assay
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: bevacizumab (bevacizumab) — if eligible per standard of care
Prior bevacizumab treatment is required, if eligible per standard of care
Must have received: PARP inhibitor — if BRCA 1/2 mutation or HRD, if eligible per standard of care
Prior PARP inhibitor treatment is required if BRCA 1/2 mutation or HRD, if eligible per standard of care
Must have received: mirvetuximab (mirvetuximab) — if eligible per standard of care
Prior mirvetuximab treatment is required, if eligible per standard of care
Cannot have received: WEE1 inhibitor (ZN-c3)
Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.
Cannot have received: ATR inhibitor
Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.
Cannot have received: PKMYT1 inhibitor
Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.
Cannot have received: CHK1/2 inhibitor
Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.
Lab requirements
Blood counts
Adequate hematologic function, as defined in protocol
Kidney function
Adequate organ function, as defined in protocol
Liver function
Adequate organ function, as defined in protocol
Adequate hematologic and organ function, as defined in protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 0170-USA Mitchell Cancer Institute · Mobile, Alabama
- Site 0143 - HonorHealth · Phoenix, Arizona
- Site 0102 - University of Arizona Cancer Center · Tucson, Arizona
- Site 0258 - UC San Diego Moores Cancer Center · La Jolla, California
- Site 0287 - Ridley Tree Cancer Center · Santa Barbara, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05128825 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor disqualifies patients from enrollment.
Does this trial require CCNE1?
Yes, CCNE1 protein overexpression is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages